Neos Therapeutics Inc. | Key People and Executives
Gerald W. McLaughlin
President, Chief Executive Officer & Director
Linda M. Szyper
Independent Director
Bryant E. Fong
Independent Director
Greg J. Robitaille
Independent Director
Beth P. Hecht
Independent Director
John P. Schmid
Independent Director
Gerald W. McLaughlin
President, Chief Executive Officer & Director
Margaret Cabano
Vice President-Operations
Richard I. Eisenstadt
Chief Financial Officer
Thomas P. Mcdonnell
Chief Commercial Officer
Carolyn R. Sikes
Vice President-Clinical Affairs
Russell Lee McMahen
Vice President-Research & Development
Asif Mughal
Vice President-Quality Assurance
Steven M. Lutz
Vice President-Sales
Dorothy Engelking
Vice President-Regulatory Affairs
Linda M. Szyper
Independent Director
Bryant E. Fong
Independent Director
Greg J. Robitaille
Independent Director
Beth P. Hecht
Independent Director
John P. Schmid
Independent Director
| Address |
2940 North Highway 360
Grand Prairie Texas 75050
United States
|
|
Employees
|
- |
| Website |
http://www.neostx.com |
| Updated |
07/08/2019 |
| Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company's extended-release technology platform. In addition, Neos manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. |
